Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?

被引：6

作者：

Ahluwalia, R. ^{[1
]}

Perkins, K. ^{[1
]}

Ewins, D. ^{[1
]}

Goenka, N. ^{[1
]}

机构：

[1] Countess Chester NHS Fdn, Ctr Diabet, Chester, Cheshire, England

来源：

DIABETIC MEDICINE | 2009年 / 26卷 / 08期

关键词：

D O I：

10.1111/j.1464-5491.2009.02753.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：834 / 835

页数：2

共 4 条

[1] Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice [J].

Ahrén, B ;

Winzell, MS ;

Burkey, B ;

Hughes, TE .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 521 (1-3) :164-168

[2] Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin [J].

Lumb, Alistair N. ;

Gallen, Ian W. .

DIABETIC MEDICINE, 2009, 26 (02) :189-190

[3] Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1α gene mutations:: evidence for pharmacogenetics in diabetes [J].

Pearson, ER ;

Liddell, WG ;

Shepherd, M ;

Corrall, RJ ;

Hattersley, AT .

DIABETIC MEDICINE, 2000, 17 (07) :543-545

[4] The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide - Regardless of etiology and phenotype [J].

Vilsboll, T ;

Knop, FK ;

Krarup, T ;

Johansen, A ;

Madsbad, S ;

Larsen, S ;

Hansen, T ;

Pedersen, O ;

Holst, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4897-4903

← 1 →